FORE Biotherapeutics Secures $110M Total Funding for Groundbreaking BRAF Cancer Drug
July 11, 2026, 3:50 am
Location: United States, California, Santa Clara
Employees: 11-50
Founded date: 2018
FORE Biotherapeutics secured $67.4 million, completing its Series D-2 funding at $110 million. This capital fuels plixorafenib, a next-generation BRAF inhibitor. The drug targets challenging BRAF-altered cancers, including primary CNS tumors. Crucial topline data from the global FORTE study are anticipated late 2026. A 2027 FDA submission is slated under Accelerated Approval, reinforced by Breakthrough Therapy Designation. This significant investment accelerates precision oncology. It promises improved outcomes for patients with difficult-to-treat malignancies, addressing prior therapy limitations. The market for targeted treatments expands, offering new hope.
FORE Biotherapeutics fortifies its financial position. The Philadelphia-based oncology firm announced a substantial $67.4 million Series D-2 extension. This finalizes the Series D-2 round at an impressive $110 million. The investment signals strong confidence in FORE’s pipeline. This capital influx empowers the company’s lead targeted cancer therapy.
Plixorafenib stands at the forefront. This drug, also known as FORE8394, is a next-generation BRAF inhibitor. It represents a significant advance in precision medicine. BRAF mutations are common drivers in many cancers. Targeting these mutations offers a pathway to effective treatment. Plixorafenib addresses limitations of earlier BRAF therapies. It aims to prevent rapid recurrence. It seeks to reduce reliance on complex combination regimens. Its novel mechanism provides a differentiated approach.
A powerful syndicate of investors backed the funding. SR One, Medicxi, and SymBiosis co-led the financing efforts. Several new investors joined the strategic group. TaiAx, LG Technology Ventures, Primer Ventures, and Axil came on board. Existing investors also reaffirmed their commitment. This roster included OrbiMed Advisors, HBM Healthcare Investments, Wellington Management, Cormorant Capital, Novartis Venture Fund, Windham Life Science Partners, Samsung, and 3B Capital. Their continued support validates FORE’s vision.
The proceeds will accelerate plixorafenib’s late-stage development. Key milestones include generating pivotal clinical data. Regulatory preparations are also paramount. Expanding the therapy’s reach to additional indications forms a core strategy. Each step is critical for patient access.
The global FORTE study is central to these plans. This Phase 2 trial meticulously evaluates plixorafenib. It spans diverse patient populations. A primary focus lies on BRAF V600E primary central nervous system (CNS) tumors. These cancers are often aggressive and difficult to treat. Enrollment for this specific basket has concluded. Approximately 50 patients participated in this crucial segment. Topline results are eagerly awaited by late 2026. These findings will determine the next steps.
Positive outcomes from FORTE could pave the way for an FDA submission. The company projects this submission in 2027. It intends to utilize the Accelerated Approval pathway. This expedited route can significantly shorten time to market. Plixorafenib has already received significant regulatory recognition. The FDA granted Breakthrough Therapy Designation in April 2026. This status accelerates the drug’s review process. It highlights the therapy's potential to address unmet medical needs in serious conditions.
FORTE study protocols have evolved. The trial now includes younger patients. Access extends to children as young as eight years old. This expansion acknowledges the prevalence of BRAF-altered CNS tumors in pediatric populations. The drug’s administration also saw improvements. Plixorafenib can now be taken with food. This eliminates the prior requirement for a pharmacokinetic booster, cobicistat. These practical adjustments improve patient experience. They enhance study feasibility.
Plixorafenib's therapeutic potential extends beyond CNS tumors. The company actively pursues development in other monotherapy indications. These encompass rare BRAF V600-mutated solid tumors. Advanced solid tumors featuring BRAF fusions are also targets. Earlier Phase 1/2 studies demonstrated encouraging activity. Plixorafenib showed meaningful response rates. It maintained a favorable safety profile across multiple tumor types. Drug-related treatment discontinuations remained below 2%. This robust safety profile is vital for long-term use.
Precision oncology defines the future of cancer care. It meticulously matches treatments to individual genetic mutations. BRAF mutations are significant oncogenic drivers. They appear in melanomas, thyroid cancers, and certain brain tumors. Drug developers continuously seek more effective BRAF inhibitors. FORE Biotherapeutics positions plixorafenib as a leading contender. Its differentiated mechanism offers hope. It targets both V600 and non-V600 BRAF alterations. This broadens its potential application.
The substantial investment reflects a thriving market. Investors increasingly favor therapies with precise mechanisms of action. They prioritize solutions for high unmet medical needs. Plixorafenib embodies this approach. It represents a novel strategy against aggressive cancers. Its potential to transform patient outcomes is clear.
FORE Biotherapeutics anticipates multiple key milestones. The period through 2026 and 2027 will be transformative. Clinical advancements and regulatory decisions are on the horizon. These steps are crucial for bringing plixorafenib to market. The company aims to deliver advanced, targeted therapies. It seeks to improve outcomes for patients battling the hardest-to-treat cancers. This funding fuels that critical mission.
FORE Biotherapeutics fortifies its financial position. The Philadelphia-based oncology firm announced a substantial $67.4 million Series D-2 extension. This finalizes the Series D-2 round at an impressive $110 million. The investment signals strong confidence in FORE’s pipeline. This capital influx empowers the company’s lead targeted cancer therapy.
Plixorafenib stands at the forefront. This drug, also known as FORE8394, is a next-generation BRAF inhibitor. It represents a significant advance in precision medicine. BRAF mutations are common drivers in many cancers. Targeting these mutations offers a pathway to effective treatment. Plixorafenib addresses limitations of earlier BRAF therapies. It aims to prevent rapid recurrence. It seeks to reduce reliance on complex combination regimens. Its novel mechanism provides a differentiated approach.
A powerful syndicate of investors backed the funding. SR One, Medicxi, and SymBiosis co-led the financing efforts. Several new investors joined the strategic group. TaiAx, LG Technology Ventures, Primer Ventures, and Axil came on board. Existing investors also reaffirmed their commitment. This roster included OrbiMed Advisors, HBM Healthcare Investments, Wellington Management, Cormorant Capital, Novartis Venture Fund, Windham Life Science Partners, Samsung, and 3B Capital. Their continued support validates FORE’s vision.
The proceeds will accelerate plixorafenib’s late-stage development. Key milestones include generating pivotal clinical data. Regulatory preparations are also paramount. Expanding the therapy’s reach to additional indications forms a core strategy. Each step is critical for patient access.
The global FORTE study is central to these plans. This Phase 2 trial meticulously evaluates plixorafenib. It spans diverse patient populations. A primary focus lies on BRAF V600E primary central nervous system (CNS) tumors. These cancers are often aggressive and difficult to treat. Enrollment for this specific basket has concluded. Approximately 50 patients participated in this crucial segment. Topline results are eagerly awaited by late 2026. These findings will determine the next steps.
Positive outcomes from FORTE could pave the way for an FDA submission. The company projects this submission in 2027. It intends to utilize the Accelerated Approval pathway. This expedited route can significantly shorten time to market. Plixorafenib has already received significant regulatory recognition. The FDA granted Breakthrough Therapy Designation in April 2026. This status accelerates the drug’s review process. It highlights the therapy's potential to address unmet medical needs in serious conditions.
FORTE study protocols have evolved. The trial now includes younger patients. Access extends to children as young as eight years old. This expansion acknowledges the prevalence of BRAF-altered CNS tumors in pediatric populations. The drug’s administration also saw improvements. Plixorafenib can now be taken with food. This eliminates the prior requirement for a pharmacokinetic booster, cobicistat. These practical adjustments improve patient experience. They enhance study feasibility.
Plixorafenib's therapeutic potential extends beyond CNS tumors. The company actively pursues development in other monotherapy indications. These encompass rare BRAF V600-mutated solid tumors. Advanced solid tumors featuring BRAF fusions are also targets. Earlier Phase 1/2 studies demonstrated encouraging activity. Plixorafenib showed meaningful response rates. It maintained a favorable safety profile across multiple tumor types. Drug-related treatment discontinuations remained below 2%. This robust safety profile is vital for long-term use.
Precision oncology defines the future of cancer care. It meticulously matches treatments to individual genetic mutations. BRAF mutations are significant oncogenic drivers. They appear in melanomas, thyroid cancers, and certain brain tumors. Drug developers continuously seek more effective BRAF inhibitors. FORE Biotherapeutics positions plixorafenib as a leading contender. Its differentiated mechanism offers hope. It targets both V600 and non-V600 BRAF alterations. This broadens its potential application.
The substantial investment reflects a thriving market. Investors increasingly favor therapies with precise mechanisms of action. They prioritize solutions for high unmet medical needs. Plixorafenib embodies this approach. It represents a novel strategy against aggressive cancers. Its potential to transform patient outcomes is clear.
FORE Biotherapeutics anticipates multiple key milestones. The period through 2026 and 2027 will be transformative. Clinical advancements and regulatory decisions are on the horizon. These steps are crucial for bringing plixorafenib to market. The company aims to deliver advanced, targeted therapies. It seeks to improve outcomes for patients battling the hardest-to-treat cancers. This funding fuels that critical mission.